NasdaqGM:MIRMBiotechs
How Investors May Respond To Mirum Pharmaceuticals (MIRM) Profitability, Raised Guidance, and Positive Liver Disease Data
Mirum Pharmaceuticals recently reported strong third-quarter financial results, including a swing to profitability and substantial year-over-year revenue growth, alongside raising its full-year 2025 revenue guidance to the upper end of its prior range.
The company also announced new and positive clinical data for its key therapies, LIVMARLI and volixibat, to be featured at the American Association for the Study of Liver Diseases’ (AASLD) 2025 Liver Meeting, underscoring advances in...